secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003966
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics reports preliminary Q4 revenue over $20M, record treatment session revenue
--------------------------------------------------------------------------------

- Preliminary Q4 2023 total revenue >$20M (guidance $19-21M); U.S. NeuroStar system revenue ~$4.5M on 59 system shipments.
- U.S. Treatment Session revenue >$14.5M (company record, +20% YoY); local consumable revenue +33% YoY.
- Generated positive cash flow >$1M in Q4; ended 2023 with cash and equivalents ~$59M.
- Full year 2023 preliminary revenue >$71M (guidance $70-72M); momentum cited across key customer segments.
- Next phase of Better Me Guarantee Provider pilot to launch Jan 22, 2024 with ~100 sites; over 275 sites eligible later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524003966/0001193125-24-003966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524003966/d291263d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer